Biotech

All Articles

Bicara, Zenas look for IPOs to push late-phase assets towards market

.Bicara Therapeutics as well as Zenas Biopharma have offered fresh incentive to the IPO market with ...

Genentech to shut cancer immunology investigation division

.Genentech is going to close its own cancer immunology research division, as well as unit head as we...

Kezar falls solid lump however to prove its well worth in period 1 test

.Kezar Lifestyle Sciences is falling its dim stage 1 solid growth medicine as the biotech goes all-i...

Acelyrin drops izokibep, dismisses 3rd of personnel

.Despite izokibep maintaining its own newly found winning streak in the clinic, Acelyrin is no more ...

Rivus' period 2 obesity-related heart failure trial reaches endpoint

.Rivus Pharmaceuticals has plumped up the prospects of its own fat-busting, muscle-sparing drug cand...

Ovid halts preclinical work, IV program after soticlestat fail

.Ovid Therapy actually showed last month that it was actually trimming its own head count as the bus...

Eli Lilly opens $700M nucleic acid R&ampD facility in Boston ma Seaport

.Eli Lilly has actually opened up a $700 million R&ampD center in the Boston Seaport, increasing its...

Boundless Biography helps make 'modest' layoffs 5 months after $100M IPO

.Simply five months after securing a $100 million IPO, Boundless Biography is already giving up some...

Halda's $126M is going to accelerate 'hold as well as kill' lump medications

.The initial phases of oncology R&ampD may not be short of intriguing brand new methods, and Halda R...

Lykos 'remorses' certainly not divulging research study offenses along with author

.Psychopharmacology has pulled three write-ups concerning midstage scientific trial information dete...